Sepsis and Coronavirus Disease 2019: Common Features and Anti-Inflammatory Therapeutic Approaches
From Critical Care Medicine. The authors present some common features shared by severe coronavirus disease 2019 patients and sepsis and describe proposed anti-inflammatory therapies for coronavirus disease 2019 which have been previously evaluated in sepsis.
Foreword: Does Severe Acute Respiratory Syndrome Coronavirus 2 Cause Sepsis?
From Critical Care Medicine. In this foreword, the authors contend that there should be no debate that SARS-CoV-2 is an important cause of sepsis and that labeling it as such is beneficial and appropriate.
Editorial: Pediatric Sepsis in the Time of Coronavirus Disease 2019
From Pediatric Critical Care Medicine. In this editorial, the author reviews ""Perspectives on Pediatric Sepsis in Patients with COVID-19"" from the Surviving Sepsis Campaign Pediatric Guidelines Taskforce authors.
Editorial: Coronavirus Disease 2019: A Tsunami of Data and a Plethora of Unanswered Questions
From Pediatric Critical Care Medicine. In this editorial, the author discusses issues emerging from the study by Bhumbra et al. (Clinical features of critical coronavirus disease 2019 in children) that are worthy of discussion and further exploration, including the predilection for racial minorities, similarities and differences to sepsis, wide expression of clinical disease, and the conundrum of providing family centered care.
Perspective of the Surviving Sepsis Campaign on the Management of Pediatric Sepsis in the Era of Coronavirus Disease 2019
From Pediatric Critical Care Medicine. In this article, the authors discuss the Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-associated Organ Dysfunction in Children as they relate to COVID-19.
Consideration of Severe Coronavirus Disease 2019 As Viral Sepsis and Potential Use of Immune Checkpoint Inhibitors
From Critical Care Explorations. Supportive treatment and immunomodulators have a critical place in the treatment of severe patients until effective antivirals are developed. Interleukin-6 antagonists, one of the immunomodulating agents, appears to be effective in the treatment of cytokine storm, but some patients continue to have severe lymphopenia and immunosuppression.
Sepsis and COVID-19
This presentation is an overview of sepsis management in COVID-19 patient. This is SCCM curated COVID-19 microlearning content.